
61Vc+c-LNbL._AC_UF1000,,

Pharmacokinetic-Pharmacodynamic Modeling and Simulation,

Modeling Pharmacokinetics and Pharmacodynamics of,

Population pharmacokinetic, pharmacodynamic and efficacy,

Physiologically based pharmacokinetic modelling to guide,

Defining preclinical efficacy with the DNAPK inhibitor,

Utilizing physiologically-based pharmacokinetic models to,

Defining preclinical efficacy with the DNAPK inhibitor,

fphar-15-1378034-g001.jpg,

Population pharmacokinetic, pharmacodynamic and efficacy,

Modeling Pharmacokinetics and Pharmacodynamics of,

Recent Advances in Translational Pharmacokinetics and,

Frontiers | Predicting pharmacodynamic effects through early,

Physiologicaly based pharmacokinetic modelling of,

A quantitative modeling framework to understand the